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Acute myocardial infarction (AMI) is usually seen in the setting of atherosclerosis and its associated risk factors.
Myocardial infarction in the young poses a particular challenge, as the disease is less likely, due to atherosclerosis. We
report the case of a 37-year-old female patient who presented with ST segment elevation anterolateral AMI. The only
abnormality on routine blood investigation was raised hemoglobin and hematocrit. After further testing, she was
diagnosed according to the World Health Organization (WHO) criteria with polycythemia vera. This case illustrates the
importance of recognizing polycythemia vera as an important cause of thrombosis, which can present initially as AMI,
and to emphasize the early recognition of the disease in order to initiate appropriate management strategies.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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A 37-year-old Egyptian woman presented toour Emergency Department with severe ret-
rosternal compressive chest pain over a three-
hour period. The pain was radiating to both shoul-
ders and was associated with profuse sweating.
She had no previous history of hypertension,
diabetes mellitus or hyperlipidemia. She was a
lifetime non-smoker. She took no recreational
drugs and did not have family history of cardiac
disease.On physical examination, she looked plethoric
with conjunctival congestion. Her temperature
was 37 C, pulse 90/min (regular), blood pressure
(BP) 130/85 mmHg, respiratory rate 18/min and
saturation in room air 99%. Her chest, heart and
abdominal examination revealed no abnormality.
The peripheral pulses were all intact.
The ECG on admission (Fig. 1) showed ST seg-
ment-elevation in anterolateral leads (V1–V6 and
I-AVL), so the impression was acute ST segment
elevation myocardial infarction. Due to the
Figure 1. Twelve-lead ECG showing ST segment elevation in chest leads from V1 to V6 and limb leads I; AVL indicating extensive anterolateral
AMI.
Figure 2. Bone marrow aspirate with Romanowsky stain showing a
megakaryocyte surrounded by myeloid elements and erythroid
precursors.
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at our hospital or at a nearby facility, the patient
was thrombolyzed with reteplase 10 units IV
bolus, then 10 units given over 30 min, after ruling
out contraindications. She was started on enoxap-
arin 1 mg/kg, aspirin 81 mg, clopidogrel 75 mg,Table 1. WHO criteria for diagnosing Polycythemia Vera [3,20].
A criteria
I. Elevated red cell mass >25% above mean normal predicted
II. No cause of secondary erythrocytosis, including familial ery
truncated erythropoietin or inappropriate erythropoietin pr
III. Splenomegaly
IV. Clonal genetic abnormality other than Philadelphia chromo
V. Endogenous erythroid colony formation in vitro
B criteria
I. Thrombocytosis >400  109/L
II. Leukocytosis >12  109/L
III. Bone marrow biopsy showing panmyelosis with prominent
IV. Low serum erythropoietin
Diagnosis requires the presence of first 2 A criteria plus either any 1 other Alisinopril 10 mg, bisoprolol 10 mg and simvastatin
20 mg.
Laboratory investigations on admission were as
follows (normal range is shown in brackets): WBC
11  109/L (4–11  109/L); neutrophils 58.8%; lym-
phocytes 33%; Hb 164 g/L (118–148 g/L); hemato-
crit 0.501 L/L (0.36–0.44 L/L); MCV 83.4 FL (82–
98 FL); and platelets 448  109/L/L (150–450  109/
L). Her coagulation profile, renal function test,
liver function test, and electrolytes were all within
normal ranges.
The maximum troponin was 34.73 lg/L (upper
limit of normal 0.3 lg/L); lipid profile showed tri-
glyceride of 3.97 mmol/L (0–1.7 mmol/L); HDL
0.86 mmol/L (1.29–1.69 mmol/L); and LDL
1.53 mmol/L (0–3.4 mmol/L).
In pursuit of the cause for her polycythemia, fur-
ther tests were done. The arterial blood gas
showed no hypoxia, the erythropoietin level was
1.11 mU/ml (4.30–29 mU/ml), and the JAK-2
V617F mutation was positive. Cytogenetic study
for BCR/ABL1 rearrangement was negative. The
tests for ANA, lupus anticoagulant, anticardiolipin
antibody and antib2 glycoprotein were negative.value, or hemoglobin >18.5 g/dL in men, 16.5 g/dL in women
throcytosis, hypoxia, high oxygen affinity hemoglobin,
oduction by tumor
some or BCR-ABL fusion gene in marrow cells.
erythroid and megakaryocytic proliferation
criterion or 2 B criteria.
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MYOCARDIAL INFARCTION: AN UNUSUAL PRESENTATIONThe abdominal ultrasound was normal with no
hepatosplenomegaly. The patient’s echocardiog-
raphy showed ejection fraction of 60% with no
intracardiac thrombus.
The bone marrow aspirate and biopsy (Fig. 2)
showed increase in trilineage hematopoiesis with
an increased number of megakaryocytes present
in loose clusters with a degree of pleomorphism.
These findings are morphologically in keeping
with myeloproliferative disorder. Based on the
clinical picture and laboratory results, the patient
was diagnosed with polycythemia vera (PV) fulfill-
ing the WHO diagnostic criteria (Table 1), and
started on hydroxyurea 15 mg/kg, aspirin 81 mg,
and scheduled for regular phlebotomy to keep
hematocrit less than 45%.
Four weeks later, the patient had myocardial
perfusion scintigraphy, which showed no evi-
dence of myocardial ischemia. CT coronary angi-
ography was normal.Discussion
Polycythemia vera (PV) is a primary disorder of
bone marrow stem cells resulting in overproduc-
tion of red cells and, to a lesser extent, neutrophils
and platelets. The median age of diagnosis is
60 years, though the disorder can occur in all age
groups [1]. PV occurs with a slight predominance
in men. The incidence is 2.3 per 100,000 persons
per year [2].
It can be discovered incidentally after routine
blood investigation or may present with signs
and symptoms related mainly to thrombosis
and/or hemorrhage. Thrombotic events in both
the venous and arterial systems are common.
Nineteen percent of 1213 patients followed by
the Gruppo Italiano Studio Policitemia suffered a
thrombotic event, of which 50% were arterial [9].
The pathophysiology of thromboembolic events
has not been illustrated in PV, but many factors
are involved including the increase in hematocrit
and blood hyperviscosity, stimulation of platelet
aggregation and thrombogenesis, the presence of
leukocytosis and intimal proliferation [4–5].
Benita reported a 30-year-old male patient who
died due to myocardial infarction as initial mani-
festation of PV. On autopsy, the vessels showed
neither arteriosclerotic changes nor thrombotic
occlusion but a marked intimal proliferation lead-
ing to multiple occlusions [6].
Coronary events are not uncommon during the
course of PV. Rossi et al. followed 149 patient diag-
nosed with PV for 10 years and found that 11.4%
had myocardial infarction [7]. Another report byMalak et al. concluded that 4% of all patients with
myeloproliferative disorder die from myocardial
infarction [8].
Despite the association of PV with coronary
artery disease, the presentation of PV as AMI is
very rare. The authors found some reports [10–
18] documenting PV presenting as AMI. Not all
papers were available for review but the majority
of cases were young males with minimal coronary
occlusion. Goethals described the difficulty of
maintaining a patent coronary artery due to
repeated thrombosis [15]. Despite evidence of
the effectiveness of new therapies in reducing
the risk of stent thrombosis, early recognition
and improved perfusion in PV are critical, as stent
thrombosis is common [19].
The major goal of treatment is to prevent throm-
botic events. Our patient was scheduled for regu-
lar phlebotomies to keep hematocrit less than
45%. In addition, she was commenced on
hydroxyurea 15 mg/kg and aspirin 81 mg/kg. The
use of angioplasty and stenting is challenged by
the development of stent thrombosis. Hydroxy-
urea is an important component of the treatment
of such patients.
In conclusion, there is no doubt that MI
accounts for a substantial percentage of morbidity
and mortality in patients with PV. Although rela-
tively rare, AMI can be the initial manifestation
of myeloproliferative disease. Attending physi-
cians should keep a high index of suspicion for
PV, especially when a young person presents with
myocardial infarction in the absence of atheroscle-
rotic risk factors, as initiation of early management
will alter patient prognosis.References
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